NEW YORK and LONDON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that new data on Coversin efficacy in eculizumab resistant patients will be presented at the 57th American Society of

NEW YORK and LONDON, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a previously announced private placement financing with a

EW YORK, NY and LONDON, UNITED KINGDOM--(Marketwired - July 13, 2015) - Celsus Therapeutics ( CLTX ) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals

NEW YORK and LONDON, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq: CLTX ), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and

NEW YORK and LONDON, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq: CLTX ), an emerging growth, development-stage biopharmaceutical company, announced today that the Company has completed enrollment of C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to

NEW YORK and LONDON, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq: CLTX ), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug Application (IND) for the clinical

NEW YORK and LONDON, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq: CLTX ), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief executive officer, is scheduled to present at the Oppenheimer 25 th  Annual Healthcare Conference

Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company MRX-6 treatment for eczema has been selected as one of the “Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Windhover Information, of Elsevier Business

NEW YORK and LONDON, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of biopharmaceutical industry veteran Allan Shaw to the Company's Board of Directors. Mr.

NEW YORK and LONDON, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.